> top > docs > PMC:7205724 > spans > 18009-18542 > annotations

PMC:7205724 / 18009-18542 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
633 59-68 Species denotes 2019-nCoV Tax:2697049
634 293-301 Species denotes patients Tax:9606
635 5-13 Species denotes patients Tax:9606
636 98-107 Disease denotes infection MESH:D007239
637 307-314 Disease denotes COVID19 MESH:C000657245
638 433-440 Disease denotes COVID19 MESH:C000657245
639 524-532 Disease denotes COVID-19 MESH:C000657245

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T137 132-137 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T138 214-217 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T139 222-225 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T140 357-371 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T20 132-137 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T133 98-107 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T134 307-314 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T135 433-440 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T136 524-532 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T224 45-47 http://purl.obolibrary.org/obo/CLO_0008192 denotes NP
T225 115-117 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T226 245-247 http://purl.obolibrary.org/obo/CLO_0008192 denotes NP
T227 251-253 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T228 283-285 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T156 45-47 Chemical denotes NP http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425
T159 245-247 Chemical denotes NP http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T13 357-371 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T78 98-107 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T79 178-185 http://purl.obolibrary.org/obo/OGMS_0000020 denotes symptom

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T179 59-68 Species denotes 2019-nCoV NCBItxid:2697049
T180 307-314 Species denotes COVID19 NCBItxid:2697049
T181 433-440 Species denotes COVID19 NCBItxid:2697049
T182 524-532 Species denotes COVID-19 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T145 0-119 Sentence denotes Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22].
T146 120-315 Sentence denotes Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19.
T147 316-441 Sentence denotes Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19.
T148 442-533 Sentence denotes It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T20 132-137 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
635 5-13 Species denotes patients Tax:9606
633 59-68 Species denotes 2019-nCoV Tax:2697049
636 98-107 Disease denotes infection MESH:D007239
634 293-301 Species denotes patients Tax:9606
637 307-314 Disease denotes COVID19 MESH:C000657245
638 433-440 Disease denotes COVID19 MESH:C000657245
639 524-532 Disease denotes COVID-19 MESH:C000657245

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1971 52-55 Protein denotes RBD https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022
T1980 267-270 Protein denotes RBD https://www.uniprot.org/uniprot/Q63492|https://www.uniprot.org/uniprot/Q63491|https://www.uniprot.org/uniprot/Q62815|https://www.uniprot.org/uniprot/Q62691|https://www.uniprot.org/uniprot/Q01542|https://www.uniprot.org/uniprot/P27732|https://www.uniprot.org/uniprot/O09024|https://www.uniprot.org/uniprot/O09023|https://www.uniprot.org/uniprot/O09022

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T8813 0-4 JJS denotes Most
T48684 5-13 NNS denotes patients
T37814 14-21 VBP denotes develop
T41895 22-32 NNS denotes antibodies
T32237 33-40 IN denotes against
T55833 41-44 DT denotes the
T23466 45-47 NN denotes NP
T51386 48-51 CC denotes and
T97267 52-55 NN denotes RBD
T48238 56-58 IN denotes of
T17626 59-68 NN denotes 2019-nCoV
T87676 69-75 IN denotes during
T56543 76-79 DT denotes the
T74019 80-86 JJ denotes second
T36179 87-91 NN denotes week
T61939 92-97 IN denotes after
T53819 98-107 NN denotes infection
T47949 108-113 NN denotes onset
T10621 114-115 -LRB- denotes [
T31327 115-117 CD denotes 22
T53799 117-118 -RRB- denotes ]
T76985 120-128 NN denotes Analysis
T6758 129-131 IN denotes of
T88720 132-137 NN denotes serum
T73739 138-145 NNS denotes samples
T20072 146-155 VBD denotes collected
T30704 156-158 CD denotes 14
T66398 159-161 CC denotes or
T43796 162-166 JJR denotes more
T64515 167-171 NNS denotes days
T88119 172-177 IN denotes after
T33297 178-185 NN denotes symptom
T78997 186-191 NN denotes onset
T69102 192-200 VBD denotes revealed
T51393 201-210 NN denotes detection
T49412 211-213 IN denotes of
T86080 214-217 NN denotes IgG
T42365 218-221 CC denotes and
T24248 222-225 NN denotes IgM
T84785 226-236 NNS denotes antibodies
T33598 237-244 IN denotes against
T65176 245-247 NN denotes NP
T29543 248-250 IN denotes in
T67075 251-253 CD denotes 94
T4274 253-254 NN denotes %
T73088 255-258 CC denotes and
T74097 259-261 CD denotes 88
T71868 261-262 NN denotes %
T54079 263-266 CC denotes and
T73098 267-270 NN denotes RBD
T69539 271-273 IN denotes in
T87988 274-277 CD denotes 100
T78691 277-278 NN denotes %
T18580 279-282 CC denotes and
T46489 283-285 CD denotes 94
T64615 285-286 NN denotes %
T60810 287-292 IN denotes among
T38563 293-301 NNS denotes patients
T93829 302-306 IN denotes with
T24980 307-314 NN denotes COVID19
T89545 316-323 NNS denotes Studies
T44838 324-336 RB denotes consistently
T54246 337-341 VBP denotes show
T20581 342-346 IN denotes that
T54967 347-356 VBN denotes increased
T27422 357-371 NN denotes immunoglobulin
T48431 372-378 NNS denotes levels
T7060 379-388 VBP denotes accompany
T92743 389-392 DT denotes the
T24866 393-403 NN denotes transition
T9522 404-408 IN denotes from
T69120 409-414 JJ denotes early
T81312 415-417 TO denotes to
T7048 418-422 JJ denotes late
T25388 423-429 NN denotes course
T44741 430-432 IN denotes of
T20679 433-440 NN denotes COVID19
T6735 442-444 PRP denotes It
T32751 445-450 VBZ denotes poses
T41840 451-454 DT denotes the
T21434 455-466 NN denotes possibility
T75450 467-471 IN denotes that
T55251 472-476 NN denotes IVIG
T48129 477-484 NN denotes therapy
T90120 485-490 MD denotes might
T91321 491-495 VB denotes help
T89890 496-498 TO denotes to
T64443 499-509 VB denotes accelerate
T5150 510-518 NN denotes recovery
T43666 519-523 IN denotes from
T85289 524-532 NN denotes COVID-19
R18045 T48684 T8813 arg1Of patients,Most
R91845 T48684 T37814 arg1Of patients,develop
R13100 T41895 T37814 arg2Of antibodies,develop
R35710 T37814 T32237 arg1Of develop,against
R20807 T51386 T32237 arg2Of and,against
R6800 T51386 T55833 arg1Of and,the
R22109 T23466 T51386 arg1Of NP,and
R81797 T97267 T51386 arg2Of RBD,and
R91140 T51386 T48238 arg1Of and,of
R87740 T17626 T48238 arg2Of 2019-nCoV,of
R8876 T37814 T87676 arg1Of develop,during
R35461 T36179 T87676 arg2Of week,during
R97441 T36179 T56543 arg1Of week,the
R2585 T36179 T74019 arg1Of week,second
R34363 T37814 T61939 arg1Of develop,after
R46687 T47949 T61939 arg2Of onset,after
R33556 T47949 T53819 arg1Of onset,infection
R6993 T37814 T10621 arg1Of develop,[
R3294 T31327 T10621 arg2Of 22,[
R78306 T53799 T10621 arg3Of ],[
R98284 T76985 T6758 arg1Of Analysis,of
R72949 T73739 T6758 arg2Of samples,of
R94093 T73739 T88720 arg1Of samples,serum
R64474 T76985 T20072 arg1Of Analysis,collected
R79737 T64515 T20072 arg2Of days,collected
R31087 T64515 T30704 arg1Of days,14
R58487 T30704 T66398 arg1Of 14,or
R48701 T30704 T43796 arg1Of 14,more
R91116 T20072 T88119 arg1Of collected,after
R29180 T69102 T88119 arg2Of revealed,after
R61094 T78997 T33297 arg1Of onset,symptom
R30751 T78997 T69102 arg1Of onset,revealed
R85646 T51393 T69102 arg2Of detection,revealed
R94930 T51393 T49412 arg1Of detection,of
R15007 T84785 T49412 arg2Of antibodies,of
R35220 T84785 T86080 arg1Of antibodies,IgG
R17029 T86080 T42365 arg1Of IgG,and
R36223 T24248 T42365 arg2Of IgM,and
R4871 T84785 T24248 arg1Of antibodies,IgM
R37373 T51393 T33598 arg1Of detection,against
R80609 T65176 T33598 arg2Of NP,against
R29116 T51393 T29543 arg1Of detection,in
R74727 T54079 T29543 arg2Of and,in
R31620 T4274 T67075 arg1Of %,94
R41074 T71868 T4274 arg1Of %,%
R32415 T4274 T73088 arg1Of %,and
R53047 T74097 T73088 arg2Of 88,and
R60224 T71868 T74097 arg1Of %,88
R30825 T71868 T54079 arg1Of %,and
R92508 T73098 T54079 arg2Of RBD,and
R99739 T54079 T69539 arg1Of and,in
R9744 T64615 T69539 arg2Of %,in
R73124 T78691 T87988 arg1Of %,100
R67370 T64615 T78691 arg1Of %,%
R15728 T78691 T18580 arg1Of %,and
R74845 T46489 T18580 arg2Of 94,and
R42305 T64615 T46489 arg1Of %,94
R38001 T51393 T60810 arg1Of detection,among
R89986 T38563 T60810 arg2Of patients,among
R54593 T38563 T93829 arg1Of patients,with
R6445 T24980 T93829 arg2Of COVID19,with
R86911 T54246 T44838 arg1Of show,consistently
R41127 T89545 T54246 arg1Of Studies,show
R52555 T7060 T54246 arg2Of accompany,show
R1890 T7060 T20581 arg1Of accompany,that
R15150 T48431 T54967 arg2Of levels,increased
R79272 T48431 T27422 arg1Of levels,immunoglobulin
R9994 T48431 T7060 arg1Of levels,accompany
R27595 T24866 T7060 arg2Of transition,accompany
R10059 T24866 T92743 arg1Of transition,the
R64970 T24866 T9522 arg1Of transition,from
R11593 T25388 T9522 arg2Of course,from
R11280 T7048 T69120 arg1Of late,early
R61089 T7048 T81312 arg1Of late,to
R36970 T25388 T7048 arg1Of course,late
R76248 T25388 T44741 arg1Of course,of
R16578 T20679 T44741 arg2Of COVID19,of
R93295 T6735 T32751 arg1Of It,poses
R68469 T21434 T32751 arg2Of possibility,poses
R17888 T21434 T41840 arg1Of possibility,the
R71902 T91321 T21434 arg2Of help,possibility
R4510 T91321 T75450 arg1Of help,that
R34056 T48129 T55251 arg1Of therapy,IVIG
R30440 T48129 T90120 arg1Of therapy,might
R46659 T91321 T90120 arg2Of help,might
R94505 T48129 T91321 arg1Of therapy,help
R59227 T64443 T91321 arg2Of accelerate,help
R39248 T64443 T89890 arg1Of accelerate,to
R27615 T48129 T64443 arg1Of therapy,accelerate
R41612 T5150 T64443 arg2Of recovery,accelerate
R13579 T5150 T43666 arg1Of recovery,from
R80924 T85289 T43666 arg2Of COVID-19,from

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T137 132-137 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T138 214-217 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T139 222-225 Body_part denotes IgM http://purl.org/sig/ont/fma/fma62873
T140 357-371 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T128 98-107 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T129 307-314 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T130 433-440 Disease denotes COVID19 http://purl.obolibrary.org/obo/MONDO_0100096
T131 524-532 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T8 347-378 Phenotype denotes increased immunoglobulin levels http://purl.obolibrary.org/obo/HP_0010702

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T145 0-119 Sentence denotes Most patients develop antibodies against the NP and RBD of 2019-nCoV during the second week after infection onset [22].
T146 120-315 Sentence denotes Analysis of serum samples collected 14 or more days after symptom onset revealed detection of IgG and IgM antibodies against NP in 94% and 88% and RBD in 100% and 94% among patients with COVID19.
T147 316-441 Sentence denotes Studies consistently show that increased immunoglobulin levels accompany the transition from early to late course of COVID19.
T148 442-533 Sentence denotes It poses the possibility that IVIG therapy might help to accelerate recovery from COVID-19.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T8 347-378 Phenotype denotes increased immunoglobulin levels http://purl.obolibrary.org/obo/HP_0010702